West Columbia, S.C. (Dec. 13, 2018) – Nephron 503B Outsourcing Facility launched a new opioid free pain management product in response to the current crisis in America. The product, BKK, is a multimodal analgesia containing Bupivacaine, Ketorolac and Ketamine.
BKK consists of three 20mL prefilled syringes in one convenience pack. Bupivacaine, Ketorolac and Ketamine are used together as a preventive analgesic to manage post-surgical pain. This opioid sparing product allows for a lower cost of care, diminished risk of readmission and higher patient safety outcomes.
“The overuse of opioids has caused an epidemic in our country and too many lives have unnecessarily been lost,” says Lou Kennedy, Chief Executive Officer of Nephron. “Nephron is educating, and supplying safer alternatives to surgical intervention with BKK.”
Nephron has partnered with two anesthesiologists, Dr. W. Bradley Worthington, MD of Nashville, TN, and Dr. Richard Teames, MD of Fort Worth, TX, to share the benefits of opioid free products. Together, the group is traveling nationwide to host information sessions regarding opioid free alternatives. To attend an event in your area, please reach out to Stephanie Simmonds, Chief Marketing Officer of Nephron, at (803) 743-7982 or firstname.lastname@example.org.
To purchase BKK, customers may contact their local sales representative, or call Nephron toll-free at 1-800-443-4313.
Nephron 503B Outsourcing is a division of Nephron Pharmaceuticals Corporation. This division produces pre-filled sterile syringes and IV bags for hospitals across America, in an effort to alleviate their drug shortage needs. In accordance with the DQSA draft guidance, the company follows cGMP, GDP and all quality expectations. The company has been licensed by the Food and Drug Administration as a sterile manufacturer of generic respiratory medications along with an Outsourcing Facility providing equal sterility and quality. Nephron received a 2017 ISPE/FOYA innovation award for the high level of automation present throughout the facility. For more information, please visit www.nephronpharm.com.